ArriVent Shares Plunge on Trial Failure
ArriVent BioPharma shares dropped after its lung cancer drug failed to significantly delay disease progression in a late stage trial. The therapy extended median survival modestly compared to chemotherapy. The company is now evaluating the full dataset.
Xurve View
Insights:
Xurve View
ArriVent BioPharma shares plunged 58% during morning trading after its lead oral cancer pill failed to meaningfully delay disease progression in a late-stage trial. The therapy, firmonertinib, was tested in untreated patients with advanced non-small-cell lung cancer. CEO Bing Yao said the data fell short of therapeutic goals.
